The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models.
William R. Moore
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals
Sankar N. Maity
No relevant relationships to disclose
Joel Robert Eisner
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals
Edward P. Garvey
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals
William J. Hoekstra
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals
Mark Anton Titus
No relevant relationships to disclose
Christopher Logothetis
No relevant relationships to disclose
John C. Araujo
No relevant relationships to disclose
Eleni Efstathiou
No relevant relationships to disclose
Robert J. Schotzinger
Employment or Leadership Position - Viamet Pharmaceuticals
Stock Ownership - Viamet Pharmaceuticals